Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Teva | Sorafenib | Sorafenib | 2020-11-12 | |||
Mylan | Sorafenib | Sorafenib | 2020-09-10 | |||
Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus | 2004-06-04 | |||
Interferon alfa-2a | Roferon-A | 1986-06-04 | ||||
Atezolizumab | Tecentriq | 2017-09-20 | $4,406.336 M | Q4/22-Q3/23 | ||
AstraZeneca | Tremelimumab | Imjudo | 2022-10-21 | $13 M | Y2024 | |
Tremelimumab | Tremelimumab AstraZeneca | 2023-02-20 | ||||
Merck & Co | Interferon alfa-2b | Intron A | 1986-06-04 | |||
Interferon alfa-2b | IntronA | 2000-03-09 | ||||
Peginterferon alfa-2b | PegIntron | 2001-01-19 | ||||
Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack | 2008-06-13 | ||||
Interferon alfa-2b | Viraferon | 2000-03-09 | ||||
Peginterferon alfa-2b | ViraferonPeg | 2000-05-28 | ||||
Bayer | Sorafenib | Nexavar | 2023-02-11 | 2005-12-20 | ||
Regorafenib | Stivarga | 2022-06-28 | 2012-09-27 | |||
Dr Reddys Laboratories | Sorafenib | Sorafenib | 2022-06-07 | |||
Accord Healthcare | Sorafenib | Sorafenib Accord | 2022-11-09 | |||
Horizon Therapeutics Public | Interferon gamma-1b | Actimmune | 1999-02-25 | $122.816 M | Q3/22-Q2/23 | |
Pharma& | Peginterferon alfa-2a | Pegasys | 2002-10-16 |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|